Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
3 "Seung Yong Shin"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Microbiota
Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease
Seung Yong Shin, Young Kim, Won-Seok Kim, Jung Min Moon, Kang-Moon Lee, Sung-Ae Jung, Hyesook Park, Eun Young Huh, Byung Chang Kim, Soo Chan Lee, Chang Hwan Choi, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
Intest Res 2023;21(1):148-160.   Published online June 14, 2022
DOI: https://doi.org/10.5217/ir.2021.00168
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
The fecal microbiota of Korean patients with inflammatory bowel disease (IBD) was investigated with respect to disease phenotypes and taxonomic biomarkers for diagnosis and prognosis of IBD.
Methods
Fecal samples from 70 ulcerative colitis (UC) patients, 39 Crohn’s disease (CD) patients, and 100 healthy control individuals (HC) were collected. The fecal samples were amplified via polymerase chain reaction and sequenced using Illumina MiSeq. The relationships between fecal bacteria and clinical phenotypes were analyzed using the EzBioCloud database and 16S microbiome pipeline.
Results
The alpha-diversity of fecal bacteria was significantly lower in UC and CD (P<0.05) compared to that in HC. Bacterial community compositions in UC and CD were significantly different from that of HC according to Bray-Curtis dissimilarities, and there was also a difference between community composition in UC and CD (P=0.01). In UC, alpha-diversity was further decreased when the disease was more severe and the extent of disease was greater, and community composition significantly differed depending on the extent of the disease. We identified 9 biomarkers of severity and 6 biomarkers of the extent of UC. We also identified 5 biomarkers of active disease and 3 biomarkers of ileocolonic involvement in CD. Lachnospiraceae and Ruminococcus gnavus were biomarkers for better prognosis in CD.
Conclusions
The fecal microbiota profiles of IBD patients were different from those of HC, and several bacterial taxa may be used as biomarkers to determine disease phenotypes and prognosis. These data may also help discover new therapeutic targets for IBD.

Citations

Citations to this article as recorded by  
  • Gut microbiota dysbiosis in a novel mouse model of colitis potentially increases the risk of colorectal cancer
    Abrory A. C. Pramana, Guanying Bianca Xu, Siyuan Liang, Erick Omar Garcia Vazquez, Jacob M. Allen, Brett R. Loman, Wenyan Mei, Yuan-Xiang Pan, Hong Chen
    American Journal of Physiology-Gastrointestinal and Liver Physiology.2025; 328(6): G831.     CrossRef
  • Gut bacteriome in inflammatory bowel disease: An update on recent advances
    Aditya Bajaj, Manasvini Markandey, Saurabh Kedia, Vineet Ahuja
    Indian Journal of Gastroenterology.2024; 43(1): 103.     CrossRef
  • An Update on the Role and Potential Molecules in Relation to Ruminococcus gnavus in Inflammatory Bowel Disease, Obesity and Diabetes Mellitus
    Jinni Hong, Tingting Fu, Weizhen Liu, Yu Du, Junmin Bu, Guojian Wei, Miao Yu, Yanshan Lin, Cunyun Min, Datao Lin
    Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1235.     CrossRef
  • Research advancements and perspectives of inflammatory bowel disease: A comprehensive review
    Junyi Bai, Ying Wang, Fuhao Li, Yueyao Wu, Jun Chen, Meng Li, Xi Wang, Bin Lv
    Science Progress.2024;[Epub]     CrossRef
  • Integrated Analysis of Microbiome and Metabolome Reveals Disease-Specific Profiles in Inflammatory Bowel Diseases and Intestinal Behçet’s Disease
    Yehyun Park, Jae Bum Ahn, Da Hye Kim, I Seul Park, Mijeong Son, Ji Hyung Kim, Hyun Woo Ma, Seung Won Kim, Jae Hee Cheon
    International Journal of Molecular Sciences.2024; 25(12): 6697.     CrossRef
  • Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets
    Han Na Oh, Seung Yong Shin, Jong-Hwa Kim, Jihye Baek, Hyo Jong Kim, Kang-Moon Lee, Soo Jung Park, Seok-Young Kim, Hyung-Kyoon Choi, Wonyong Kim, Woo Jun Sul, Chang Hwan Choi
    Gut Pathogens.2024;[Epub]     CrossRef
  • Potential of Gut Microbe-Derived Extracellular Vesicles to Differentiate Inflammatory Bowel Disease Patients from Healthy Controls
    Min Heo, Young Soo Park, Hyuk Yoon, Nam-Eun Kim, Kangjin Kim, Cheol Min Shin, Nayoung Kim, Dong Ho Lee
    Gut and Liver.2023; 17(1): 108.     CrossRef
  • Ruminococcus gnavus: friend or foe for human health
    Emmanuelle H Crost, Erika Coletto, Andrew Bell, Nathalie Juge
    FEMS Microbiology Reviews.2023;[Epub]     CrossRef
  • The Relationship Between Rosacea and Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
    Yu Kyung Jun, Da-Ae Yu, Yoo Min Han, Soo Ran Lee, Seong-Joon Koh, Hyunsun Park
    Dermatology and Therapy.2023; 13(7): 1465.     CrossRef
  • Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea
    Oh Chan Kwon, See Young Lee, Jaeyoung Chun, Kyungdo Han, Yuna Kim, Ryul Kim, Min-Chan Park, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Comments on Efficacy of a Synbiotic Containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in Elderly Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
    Kwang Woo Kim
    Gut and Liver.2023; 17(6): 954.     CrossRef
  • Evaluation of Bacterial and Fungal Biomarkers for Differentiation and Prognosis of Patients with Inflammatory Bowel Disease
    Hyuk Yoon, Sunghyouk Park, Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee
    Microorganisms.2023; 11(12): 2882.     CrossRef
  • A Machine Learning-Based Diagnostic Model for Crohn’s Disease and Ulcerative Colitis Utilizing Fecal Microbiome Analysis
    Hyeonwoo Kim, Ji Eun Na, Sangsoo Kim, Tae-Oh Kim, Soo-Kyung Park, Chil-Woo Lee, Kyeong Ok Kim, Geom-Seog Seo, Min Suk Kim, Jae Myung Cha, Ja Seol Koo, Dong-Il Park
    Microorganisms.2023; 12(1): 36.     CrossRef
  • 5,802 View
  • 482 Download
  • 12 Web of Science
  • 13 Crossref
Close layer
IBD
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
Seung Yong Shin, Soo Jung Park, Young Kim, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-Ho Kim, Do Hyun Kim, Dennis Teng, Jong-Hwa Kim, Wonyong Kim, Chang Hwan Choi, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
Intest Res 2022;20(3):350-360.   Published online July 23, 2021
DOI: https://doi.org/10.5217/ir.2021.00049
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
This study assessed the efficacy and safety of adalimumab (ADA) and explored predictors of response in Korean patients with ulcerative colitis (UC).
Methods
A prospective, observational, multicenter study was conducted over 56 weeks in adult patients with moderately to severely active UC who received ADA. Clinical response, remission, and mucosal healing were assessed using the Mayo score.
Results
A total of 146 patients were enrolled from 17 academic hospitals. Clinical response rates were 52.1% and 37.7% and clinical remission rates were 24.0% and 22.0% at weeks 8 and 56, respectively. Mucosal healing rates were 39.0% and 30.1% at weeks 8 and 56, respectively. Prior use of anti-tumor necrosis factor-α (anti-TNF-α) did not affect clinical and endoscopic responses. The ADA drug level was significantly higher in patients with better outcomes at week 8 (P<0.05). In patients with lower endoscopic activity, higher body mass index, and higher serum albumin levels at baseline, the clinical response rate was higher at week 8. In patients with lower Mayo scores and C-reactive protein levels, clinical responses, and mucosal healing at week 8, the clinical response rate was higher at week 56. Serious adverse drug reactions were identified in 2.8% of patients.
Conclusions
ADA is effective and safe for induction and maintenance in Korean patients with UC, regardless of prior anti-TNF-α therapy. The ADA drug level is associated with the efficacy of induction therapy. Patients with better short-term outcomes were predictive of those with an improved long-term response.

Citations

Citations to this article as recorded by  
  • Prospective Observational Evaluation of the Time-Dependency of Adalimumab Immunogenicity and Drug Concentration in Ulcerative Colitis Patients: the POETIC II Study
    Sivan Harnik, Chaya M Abitbol, Ola Haj Natour, Miri Yavzori, Ella Fudim, Orit Picard, Timna Naftali, Efrat Broide, Ayal Hirsch, Limor Selinger, Eyal Shachar, Doron Yablecovitch, Ahmad Albshesh, Daniel Coscas, Uri Kopylov, Rami Eliakim, Shomron Ben-Horin,
    Journal of Crohn's and Colitis.2024; 18(3): 341.     CrossRef
  • Rapidly achieving clinical remission in ulcerative colitis indicates better endoscopic and histological outcomes
    Rirong Chen, Yizhe Tie, Yongle Huang, Xi Zhang, Zhirong Zeng, Minhu Chen, Li Li, Shenghong Zhang
    United European Gastroenterology Journal.2024; 12(4): 459.     CrossRef
  • Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis
    Saleh Azadbakht, Masomeh Seighali, Salehe Azadbakht, Morteza Azadbakht
    Health Science Reports.2024;[Epub]     CrossRef
  • Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets
    Han Na Oh, Seung Yong Shin, Jong-Hwa Kim, Jihye Baek, Hyo Jong Kim, Kang-Moon Lee, Soo Jung Park, Seok-Young Kim, Hyung-Kyoon Choi, Wonyong Kim, Woo Jun Sul, Chang Hwan Choi
    Gut Pathogens.2024;[Epub]     CrossRef
  • Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review
    Peter M. Irving, Peter Hur, Raju Gautam, Xiang Guo, Severine Vermeire
    Journal of Managed Care & Specialty Pharmacy.2024; 30(9): 1026.     CrossRef
  • Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
    Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim
    Intestinal Research.2023; 21(1): 61.     CrossRef
  • Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis
    Seok-Young Kim, Seung Yong Shin, Soo Jung Park, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Reviewing not Homer’s Iliad, but “Kai Bao Ben Cao”: indigo dye—the past, present, and future
    Yusuke Yoshimatsu, Tomohisa Sujino, Takanori Kanai
    Intestinal Research.2023; 21(2): 174.     CrossRef
  • Precision medicine and drug optimization in adult inflammatory bowel disease patients
    Sophie Vieujean, Edouard Louis
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study
    Seung Bum Lee, Hee Seung Hong, Chang Kyun Lee, Bo-In Lee, Sol Kim, Seong-Joon Koh, Hosun Yu, Jung-Bin Park, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
    The Korean Journal of Internal Medicine.2023; 38(5): 661.     CrossRef
  • Advancements in the Management of Moderate-to-Severe Ulcerative Colitis: A Revised 2023 Korean Treatment Guidelines
    Soo-Young Na
    The Korean Journal of Medicine.2023; 98(5): 223.     CrossRef
  • Prediction of Clinical Remission with Adalimumab Therapy in Patients with Ulcerative Colitis by Fourier Transform–Infrared Spectroscopy Coupled with Machine Learning Algorithms
    Seok-Young Kim, Seung Yong Shin, Maham Saeed, Ji Eun Ryu, Jung-Seop Kim, Junyoung Ahn, Youngmi Jung, Jung Min Moon, Chang Hwan Choi, Hyung-Kyoon Choi
    Metabolites.2023; 14(1): 2.     CrossRef
  • Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program
    Marla C Dubinsky, Fernando Magro, Flavio Steinwurz, David P Hudesman, Jami A Kinnucan, Ryan C Ungaro, Markus F Neurath, Nicole Kulisek, Jerome Paulissen, Chinyu Su, Dario Ponce de Leon, Miguel Regueiro
    Inflammatory Bowel Diseases.2022;[Epub]     CrossRef
  • Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
    Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi
    Gut and Liver.2022; 16(5): 764.     CrossRef
  • Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
    Ji Young Chang, Jae Hee Cheon
    Precision and Future Medicine.2021; 5(4): 151.     CrossRef
  • 8,860 View
  • 668 Download
  • 17 Web of Science
  • 15 Crossref
Close layer
Case Report
Adenocarcinoma Originating From a Completely Isolated Duplication Cyst of the Mesentery in an Adult
Seung Yong Shin, Mee Yon Cho, Hoon Ryu, Jae Woo Kim, Hyun-Soo Kim, Jung Min Kim, An Na Ko, Tae-Sun Yu, Hong Jun Park
Intest Res 2014;12(4):328-332.   Published online October 27, 2014
DOI: https://doi.org/10.5217/ir.2014.12.4.328
AbstractAbstract PDFPubReaderePub

Alimentary tract duplications are uncommon congenital abnormalities that usually have an anatomical connection with some part of the gastrointestinal tract and have a common blood supply with the adjacent segment of intestine. A completely isolated duplication cyst (CIDC) is a very rare type of gastrointestinal duplication that does not communicate with the normal bowel segment and possesses its own exclusive blood supply. Only 5 CIDC cases in adults have been reported in the English medical literature. Additionally, only 1 case of mucinous cystadenoma from an infected CIDC of the ileum has been reported. This report describes a 52-year-old male patient with a peritoneal CIDC, which upon curative excision was found to have given rise to an adenocarcinoma. The latter was lined internally with malignant glandular cells and contained a smooth muscular outer layer as determined by microscopic examination of the tissue. We believe that this is the first reported case of an adenocarcinoma originating from a CIDC in an adult.

Citations

Citations to this article as recorded by  
  • Two Cases of Adult-Onset Intestinal Duplication Manifested as Acute Abdomen: Case Report and Review of the Literature
    Yuki Nomura, Satoshi Nagayama, Sachie Fujioka, Go Takeuchi, Yuma Takeuchi, Michio Okamoto, Riki Ganeko, Yusuke Nakayama, Kyoichi Hashimoto, Yoshihiro Kubota
    Surgical Case Reports.2025; 11(1): n/a.     CrossRef
  • Low-Grade Mucinous Neoplasm Arising in an Enteric Duplication Cyst of Pancreas: A Case Report and Literature Review
    Mengjing Fan, Fang Yang
    International Journal of Surgical Pathology.2024; 32(2): 422.     CrossRef
  • A case report of a giant ileocecal cystic prolapse through the anus and literature review
    Beige Zong, Xia Xiao, Nijiao Deng, Wenjing Wang, Li Peng, Dianliang Fang, Haoyu Wang, Song Hu, Zhongfu Li, Xin Zhang
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Jejunal duplication cyst in a female neonate: a case report
    Rajesh Prasad Sah, Amrit Bhusal, Sagar Pokhrel, Tek Nath Yogi, Sujal Labh, Kshitiz Acharya, Sushan Pokharel, Madhur Bhattarai
    Annals of Medicine & Surgery.2023; 85(11): 5724.     CrossRef
  • Adenocarcinoma arising in an ectopic enterogenous cyst: A rare case report and review of literature
    Haina Du, Dachao Xu, Shuhui Zhang, Xinliang Zhang, Mingzhi Fang, Min Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Adenocarcinoma of Jejunal Duplication Cyst—Case Report and Review of Literature
    U. V. Akshay Viswanath, Noushif Medappil, Abishek Rajan, Sajeesh Sahadevan, N. Seetha Lekshmy, K. P. Kavitha
    Indian Journal of Surgical Oncology.2021; 12(S2): 327.     CrossRef
  • Beyond the Endoscope
    Tristan Anderson, Peter J. Yuide, Terence C. Chua
    Gastroenterology.2020; 158(8): e9.     CrossRef
  • Laparoscopic excision of a retroperitoneal completely isolated enteric duplication cyst in an adult male: A case report and review of literature
    Naoya Sasaki, Miru Okamura, Satoshi Kanto, Kentaro Tatsumi, Seiichi Yasuda, Atsushi Kawabe
    International Journal of Surgery Case Reports.2018; 46: 1.     CrossRef
  • Isolated alimentary tract duplication presenting as a prenatal abdominal cyst
    Shota Ebinuma, Go Ohba, Masato Nakayama, Hiroshi Yamamoto
    Journal of Pediatric Surgery Case Reports.2018; 28: 1.     CrossRef
  • A huge completely isolated duplication cyst complicated by torsion and lined by 3 different mucosal epithelial components in an adult
    Ai Xiao-Ming, Lu Jin-Jing, Ho Li-Chen, Han Lu-Lu, Yue Xiong, Zhang Hong-Hai, Yang Nian-Yin
    Medicine.2018; 97(44): e13005.     CrossRef
  • Presacral Noncommunicating Enteric Duplication Cyst
    Shabnam Seydafkan, David Shibata, Julian Sanchez, Nam D. Tran, Marino Leon, Domenico Coppola
    Cancer Control.2016; 23(2): 170.     CrossRef
  • 5,674 View
  • 68 Download
  • 15 Web of Science
  • 11 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP